



Published in final edited form as:

Semin Reprod Med. 2014 May ; 32(3): 194–201. doi:10.1055/s-0034-1371091.

Diagnosis and Challenges of Polycystic Ovary Syndrome in Adolescence

Sophia E. Agapova, BA¹, Tamara Cameo, AB¹, Aviva B. Sopher, MD, MS¹, and Sharon E. Oberfield, MD¹

¹Division of Pediatric Endocrinology, Diabetes, and Metabolism, Department of Pediatrics, Columbia University Medical Center, New York, New York

Abstract

Although the diagnostic criteria for polycystic ovary syndrome (PCOS) have become less stringent over the years, determination of the minimum diagnostic features in adolescents is still an area of controversy. Of particular concern is that many of the features considered to be diagnostic for PCOS may evolve over time and change during the first few years after menarche. Nonetheless, attempts to define young women who may be at risk for development of PCOS is pertinent since associated morbidity such as obesity, insulin resistance, and dyslipidemia may benefit from early intervention. The relative utility of diagnostic tools such as persistence of anovulatory cycles, hyperandrogenemia, hyperandrogenism (hirsutism, acne, or alopecia), or ovarian findings on ultrasound is not established in adolescents. Some suggest that even using the strictest criteria, the diagnosis of PCOS may not valid in adolescents younger than 18 years. In addition, evidence does not necessarily support that lack of treatment of PCOS in younger adolescents will result in untoward outcomes since features consistent with PCOS often resolve with time. The presented data will help determine if it is possible to establish firm criteria which may be used to reliably diagnose PCOS in adolescents.

Keywords

polycystic ovary syndrome; polycystic ovarian morphology; type 2 diabetes mellitus

Polycystic ovary syndrome (PCOS) is a common endocrinopathy that by strictest definition affects 5 to 10% of women of reproductive age.¹ It is characterized by menstrual irregularity, hyperandrogenism, and polycystic ovarian morphology (PCOM) and is also associated with insulin resistance, obesity, and components of the metabolic syndrome (MetS).^{2,3} PCOS often presents during adolescence, but the diagnosis in this age group is complicated by the overlap between the features of PCOS and physiologic findings observed during the normal progression of puberty.⁴ Further, the diagnosis is difficult to make with certainty given the absence of universally accepted diagnostic criteria for adolescents.

© 2014 by Thieme Medical Publishers, Inc.

Address for correspondence Sharon E. Oberfield, MD, Division of Pediatric Endocrinology, Diabetes, and Metabolism, Department of Pediatrics, Columbia University Medical Center, 622 West 168th Street, PH5E-522, New York, NY 10032 (seo8@umc.columbia.edu).

Three distinct sets of diagnostic criteria have been suggested for the diagnosis of PCOS in adults. The National Institutes of Health Consensus Statement¹ proposed that PCOS be defined as menstrual irregularity (chronic anovulation or oligomenorrhea) and evidence of clinical or biochemical hyperandrogenism with the exclusion of other etiologies. The 2003 European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine Rotterdam criteria (ESHRE/ASRM)⁵ broadened the diagnosis of PCOS, requiring two of three features: anovulation or oligo-ovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovaries by ultrasound (US). Finally, the Androgen Excess and PCOS Society⁶ defined PCOS as hyperandrogenism with ovarian dysfunction or polycystic ovaries. Most recently, the NIH Evidence-Based Methodology Workshop on PCOS³ recommended use of the 2003 Rotterdam criteria with identification of specific phenotypes within the diagnosis.

As stated, at present there is not a total agreement regarding definitive criteria for the diagnosis of PCOS in adolescents. We reviewed 73 papers published since 2006 where adolescents with PCOS were described (Table 1).⁷⁻⁷⁹ Of interest, 22 studies used NIH, 42 used Rotterdam, and 8 used Androgen Excess Society (AES) or other criteria to diagnose PCOS, some using more than 1. Seven of the studies reviewed did not specify any diagnostic criteria used. Of these studies, 31 were from North America, 21 were from Asia, 14 were from Europe, 1 was from Africa, and 3 were from Australia and New Zealand. Only 22 of the studies mentioned number of years postmenarche of the subjects.

Further, the variability of diagnoses in and of PCOS poses various challenges. Use of different criteria can result in a different prevalence of PCOS, even within the same cohort.^{43,44} Clearly, while early diagnosis in adolescents may allow for earlier treatment and prevention of PCOS-associated morbidity, premature diagnosis carries risks of psychological distress and unnecessary treatment.

Numerous studies have called into question the appropriateness of applying adult criteria to adolescents because the features of PCOS are often physiologic or transitory during normal puberty.^{80,81} Thus, several adolescent-specific criteria have been proposed. Sultan and Paris⁸² suggests requiring four out of five of the following: oligomenorrhea or amenorrhea at least 2 years postmenarche, clinical hyperandrogenism, biologic hyperandrogenism, insulin resistance, and polycystic ovary morphology, while Carmina et al⁸⁰ and the 2012 ESHRE/ASRM Consensus Workshop Group⁸³ propose defining PCOS in adolescents by the presence of all three of the 2003 ESHRE/ASRM criteria: hyperandrogenism, chronic anovulation, and polycystic ovaries.

This review will discuss the components utilized by the many suggested criteria to allow one to establish the diagnosis of PCOS in adolescents as well as the ongoing challenge and controversy related to this goal.

Hyperandrogenism

Hyperandrogenism is a hallmark of PCOS; the NIH and AES criteria both require clinical and/or biochemical hyperandrogenism for the diagnosis of PCOS in adults, while the Rotterdam criteria recognize a phenotype of PCOS without androgen excess.^{1,5,6} This

feature of PCOS is especially important given its reported association with metabolic dysfunction.^{21,29,35} However, the physiologic rise in androgens that occurs during puberty makes hyperandrogenism difficult to define in adolescents. Furthermore, there is not yet a consensus regarding the preferred assay or reference values for assessing hyperandrogenemia in this age group.⁸⁴

Clinical hyperandrogenism is defined by most adult PCOS diagnostic criteria as the presence of hirsutism, acne, or androgenic alopecia.^{1,5} Hirsutism, as measured by the modified Ferriman-Gallwey (mFG) score, is recognized as the most reliable marker of clinical hyperandrogenism in women with PCOS.⁸³ In Caucasian and African American women, an mFG score of 8 is often used to define hirsutism in the diagnosis of PCOS,⁷⁰ and this cutoff has been used by numerous studies of PCOS in adolescents.⁴⁴ However, because of less cumulative time of exposure to androgens, this cutoff may require modification for use in adolescents.⁸⁵ In addition, expression of hirsutism in and of itself appears to have ethnic variability.^{86,87}

Roe et al⁷⁰ recently reported that 65% of adolescents with PCOS presented with hirsutism, which is consistent with other studies that report a high prevalence.⁴⁰ The common finding of acne in healthy adolescents, which is as high as 69%,⁴⁴ precludes its utility as a specific marker of hyperandrogenism in PCOS. Hickey et al⁴⁴ found no relationship between acne score and free testosterone (T) level or PCOM. Finally, androgenic alopecia has not been studied widely in adolescents and does not appear to be important for the assessment of hyperandrogenism in this population.⁸⁸ Of the three markers of clinical hyperandrogenism, progressive hirsutism is considered the most useful in adolescents.^{80,88}

Biochemical hyperandrogenism, a more objective measure of excess androgens, can be assessed using a variety of assays to test for serum levels of total testosterone (TT), free T, androstenedione, and dehydroepiandrosterone sulfate. The adult PCOS criteria provide little consensus and guidance as to which assay to use, albeit use of highly specific assays is increasingly being recommended.⁸⁹

The 2007 Endocrine Society position statement about the utility, limitations, and pitfalls of measuring T⁸⁴ does not specifically discuss androgens in adolescents, but suggests the use of TT assays, as opposed to free T, when measuring androgens in children. The position statement also suggests the use of T assays that use extraction and chromatography techniques, instead of direct immunoassays, to maximize sensitivity and accuracy and also stresses the need for standardized assay-specific reference values. Because of diurnal and menstrual cycle variation of T, for consistency it is recommended to be measured between 08:00 and 10:00 hours during the follicular phase.⁸⁴

More recently, liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been studied as a technique for measuring total T in adults^{90,91} and adolescents.^{92,93} Two groups^{92,93} recently developed reference ranges for total T in adolescents using LC-MS/MS and determined this method to be sufficiently sensitive and precise to be used in adolescents. Both groups measured T between 8:00 and 10:00 AM, and one made separate cutoffs based on menstrual cycle phase. However, a comparison of radioimmunoassay and LC-MS/MS

measurement of TT in women did not find a significant difference between the results of the two methods although “there is significant variability between LC/MS assays and poor precision with all assays at low T levels.”⁸⁹

Thus, while hirsutism appears to be an important clinical marker of hyperandrogenism in adolescents, and a common presenting sign of PCOS, some have argued that biochemical hyperandrogenism is a more reliable and consistent marker of hyperandrogenism in the diagnosis of PCOS in adolescents.^{4,5} Both should be evaluated in the workup of an adolescent with suspected PCOS.

Menstrual Irregularity

Menstrual irregularity is an important feature of PCOS in adults and common in the presentation of PCOS in adolescents.⁷⁰ Chronic oligo-ovulation or anovulation are included in all adult diagnostic criteria for PCOS. However, menstrual irregularity and anovulation are common among healthy adolescents, making their use in the diagnosis of PCOS in this group difficult.

In a study of 200 healthy girls, Apter and Vikho⁹⁴ found that at least 55% of menstrual cycles were anovulatory during the first 2 years postmenarche. The percentage of ovulatory cycles increased with age, reaching 80% at 4 to 5.5 years of gynecological age. While menstrual irregularity is common, its persistence after 2 years after menarche is associated with PCOS. Nair et al⁵¹ studied a cohort of 136 adolescent girls with confirmed menstrual irregularity; at 2 year follow-up, 51.5% continued to have menstrual irregularity and 36% were diagnosed with PCOS using the Rotterdam criteria. In their cohort, Roe et al⁷⁰ found that 98% of adolescents diagnosed with PCOS by the AE-PCOS criteria presented with menstrual irregularity—68.3% with oligomenorrhea, 27.7% with secondary amenorrhea, and 4% with primary amenorrhea.

There is evidence that greater menstrual irregularity is associated with a more severe PCOS phenotype and higher androgen levels.⁵ Rachmiel et al³⁰ reported that adolescents with primary amenorrhea and PCOS have increased features of MetS and higher androstenedione compared with those with oligomenorrhea. A study of a Finnish cohort found that adolescent girls with menstrual irregularity had increased T, decreased sex hormone binding globulin, and an increased free androgen index.⁵⁴ van Hooff et al found that about half of 14 to 16 year olds with oligomenorrhea remained oligomenorrheic at 18 years; body mass index (BMI) and menstrual history, but not androgen and luteinizing hormone concentrations, were predictive of persistent amenorrhea.⁹⁵

Although it is often difficult to distinguish physiologic adolescent anovulation from PCOS-related menstrual irregularity,⁹⁶ some have offered suggestions for how menstrual irregularity should be defined in adolescents and when it should be evaluated. Merino et al⁸⁸ suggested that adolescent ovulatory dysfunction should be considered with the absence of menstrual periods for longer than 90 days, or persistent cycles longer than 45 days. Rosenfield suggested evaluation for menstrual irregularity when adolescents exhibit abnormal menstruation for at least 1 year or if it is associated with other signs and symptoms.⁹⁶

The high prevalence of anovulatory cycles and menstrual irregularity in adolescence has led some to recommend that oligomenorrhea should persist for at least 2 years and that only then can PCOS be diagnosed in adolescents who are at least 2 years postmenarche.^{5,40,80} Advocates of this proposal state that because of the high frequency of menstrual irregularity in healthy adolescent girls, the diagnosis of PCOS in adolescents should not be made on the basis of menstrual irregularity alone.^{80,97}

It is interesting to speculate that although dysfunctional intermittent uterine bleeding in adolescents can be confused with normal cycling with long interval cycles, in fact, it may be that these adolescents are actually those who already have evidence of chronic anovulation. In addition, some authors suggest that measurement of progesterone is the most specific way to assess ovulation⁹⁸; however this is usually impractical in a clinical setting.

Ovarian Morphology

PCOM is included in both the AES-PCOS and Rotterdam diagnostic criteria for PCOS, which define PCOM as 12 or more follicles of 2 to 9 mm or ovarian volume $> 10 \text{ cm}^3$ in at least one ovary.⁵ Recently Dewailly et al actually suggested that the former threshold of greater than 12 follicles per ovary may even be too low and a count of 19 follicles would be needed for more accurate diagnosis.⁹⁹ In adults, transvaginal US is the standard imaging method used to evaluate ovarian morphology, however because it is inappropriate for use in virginal adolescents, transabdominal US (TA-US) is instead often used in younger patients. Polycystic ovaries are a common finding in healthy adolescents, making the use of PCOM as a diagnostic criterion for PCOS in adolescents difficult.⁸¹

Mortensen et al⁹ reported that 54% of healthy eumenorrheic girls between 1.3 and 3.8 years postmenarche had polycystic ovaries on TA-US, with a significant correlation between ovarian size and gynecological age. This correlation between increasing age and decreasing ovarian volume has also been found in adults.¹⁰⁰ Several other studies of healthy adolescents found the incidence of PCO to be 33 to 35% by TA-US.^{43,44,101} While up to half of healthy adolescents meet PCO criteria, a third of adolescents with PCOS do not.⁹⁶

Furthermore, the limitations of TA-US present a challenge in using PCOM in the diagnostic criteria for adolescents. This method is less discriminating than transvaginal US and especially difficult to use in obese patients, who make up about half of the PCOS population.⁹⁷ Transrectal US and magnetic resonance imaging (MRI) have been used in a few studies, but these methods may be less practical in a clinical setting.^{97,102}

Several authors have argued for the need for adolescent-specific thresholds for mean ovarian volume (MOV) for use in the diagnosis of PCOS. New thresholds have been suggested by groups using different imaging modalities. Villa et al⁵³ found that a MOV threshold of 5.6 mL was 89% sensitive and 80% specific for diagnosing PCOS using TA-US, while Chen et al¹⁰³ reported that a cutoff of 6.74 mL maximized specificity and sensitivity in Chinese adolescents using transvaginal US. Another study found an average MOV of 15.1 in adolescents with PCOS compared with 5.9 in healthy controls using MRI. In a comparison of TA-US and MRI in 11 obese adolescents with PCOS, Yoo et al found that MOV was not

significantly different between the two methods, but that the number of patients who met Rotterdam criteria for PCO was different between the US and MRI groups.¹⁰⁴

The limitations of using US for the detection of PCO have led to interest in anti-Müllerian hormone (AMH) as a surrogate marker. AMH is a glycoprotein secreted by granulosa cells of growing follicles and has been found to correlate with the number of small antral follicles.⁸⁸ However, reports about the utility of AMH as a marker for PCO in adolescents have been mixed. Hart et al³⁶ found that while serum AMH is significantly higher in adolescents girls with PCO, AMH level had insufficient specificity and sensitivity for detecting PCO. Villarroel et al,¹⁰¹ who studied adolescents with regular menstrual cycles, and Li et al,³⁹ who studied Chinese adolescents with PCOS, developed similar cutoffs for AMH to predict PCO with sensitivities of 64 and 61% and specificities of 89.8 and 70%, respectively. Eilertsen et al¹⁰⁵ reported that serum AMH has good accuracy for diagnosing PCOS in adults when it replaces PCOM as a criterion for PCOS diagnosis. Although more work remains to assess the use of AMH as a surrogate marker for PCO, it may prove useful as a component to aid in the diagnosis of PCOS.

Obesity, Insulin Resistance, and Metabolic Syndrome

PCOS is associated with metabolic abnormalities including insulin resistance, obesity, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease, dyslipidemia, and the MetS.^{2,4,106} There is evidence that these metabolic impairments begin as early as adolescence in women with PCOS. Although metabolic features are not included in the diagnostic criteria for PCOS, they are important to consider in adolescents given their implications on long-term health. At present, the molecular mechanisms responsible for the interactions between hyperandrogenism, obesity, and insulin resistance in PCOS are not fully understood.

Obesity is common in both adults and adolescents with PCOS. It is unclear whether PCOS predisposes women to obesity or whether obesity exacerbates PCOS.¹⁰⁷ Several studies show the prevalence of obesity in PCOS to be above 60%¹⁰⁸; Glueck et al found that 73% of adolescents with PCOS had a BMI above the 95th percentile.¹⁰⁹

While a large portion of adolescents with PCOS are obese, obesity likely does not fully explain the other metabolic features associated with PCOS. Impaired glucose tolerance (IGT), which is associated with insulin resistance and is a strong predictor for T2DM, cardiovascular disease, and premature mortality,¹¹⁰ is found at an increased rate in adolescents with PCOS. Several studies of adolescents with PCOS have reported the incidence of IGT to be 10 to 30%.^{34,37,79,111} Flannery et al⁷⁹ found that IGT occurred across the spectrum of BMI and Huang et al³⁷ found that when matched for obesity, PCOS is associated with increased risk for insulin resistance, hyperinsulinemia, and prediabetes. However, Hart et al⁴³ found that PCOS was not associated with insulin resistance after controlling for BMI, and Glueck et al found that when matched for age, PCOS subjects did not have significantly different insulin or lipid levels than healthy controls.¹⁰⁹ While IGT is the most common form of abnormal glucose metabolism found in adolescents with PCOS, impaired fasting glucose and T2DM have also been reported in this group.^{1,56,79}

MetS, a group of risk factors that increase the risk for cardiovascular disease and diabetes, is also associated with PCOS. Up to 40% of adults with PCOS have MetS.³⁴ In adolescents, multiple sets of criteria are used to define MetS and the prevalence of MetS varies among different cohorts. Most studies, however, report an increased incidence of MetS in PCOS compared with control subjects.^{21,41,52,70} Coviello et al²¹ found that 35% of girls with PCOS had MetS compared with 5% of controls and that this difference could not be accounted for by obesity alone. The reported prevalence in other studies ranges from 10 to 60%.^{41,52,70} Gleuck et al¹⁰⁹ found that a diagnosis of PCOS at age 14 was a significant independent determinant for MetS at age 24. However, in a cohort that included only obese and overweight participants, Rossi et al³⁴ reported that the prevalence of MetS did not differ significantly between PCOS and controls when matched for obesity, regardless of the definition of MetS used. Similarly, Huang et al³⁷ found that PCOS was not associated with an increased risk for MetS when matched for obesity in a Chinese adolescent cohort.

It has been proposed that the hyperandrogenism associated with PCOS contributes to the metabolic abnormalities discussed above. Fruzzetti et al³⁵ reported that hyperandrogenemia was an important risk factor for lipid alterations in adolescents with PCOS. Another study²¹ found higher levels of free T in adolescents with MetS and reported that levels of the hormone were positively correlated with BMI percentile, waist circumference, and fasting insulin. Elevated systolic and diastolic blood pressures have also been shown to be related to androgen levels in girls with PCOS.^{21,29} In a large prospective study of schoolgirls, Glueck et al¹⁰⁹ reported that low sex hormone-binding globulin was the only significant predictor of MetS and that women with MetS at 24 years of age were more likely to have had a top decile free T at age 14. However, Forrester-Dumont et al⁵⁰ found that metabolic profile was not affected by the degree of hyperandrogenism in girls with PCOS, instead, low HDL best explained the high prevalence of MetS. While most studies agree that obesity and MetS occur more frequently in adolescents with PCOS compared with the general population, the role of hyperandrogenism in this association remains controversial.

This review will not focus on therapy, however many clinical investigators still suggest that weight loss and lifestyle changes should be the first line of therapy. Metformin and oral contraceptive pills are also considered as secondary treatments that can improve the symptoms of PCOS. However, medical treatment of a condition not fully diagnosed can result in premature use of pharmacologic agents. The issue of treatment of PCOS in the adolescent further underlines the need for consensus and further research about the diagnosis of PCOS in this group. The many points of overlap between physiologic puberty and the features of PCOS may continue to suggest that a more conservative approach to the diagnosis of PCOS in adolescents compared with adults is prudent.

Acknowledgments

The authors acknowledge Dr. Selma Witchel for her thoughtful review and comments.

References

1. Zawadski, JK.; Dunaif, A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Dunaif, A.; Givens, JR.; Haseltine, F., editors. *Polycystic Ovary Syndrome*. Vol. 1992. Boston, MA: Black-well Scientific; p. 377-384.
2. Franks S. Polycystic ovary syndrome. *N Engl J Med*. 1995; 333(13):853–861. [PubMed: 7651477]
3. National Institutes of Health. Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome: Executive Summary. Washington: National Institutes of Health; 2012.
4. Roe AH, Dokras A. The diagnosis of polycystic ovary syndrome in adolescents. *Rev Obstet Gynecol*. 2011; 4(2):45–51. [PubMed: 22102927]
5. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod*. 2004; 19(1):1–7.
6. Azziz R, Carmina E, Dewailly D, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab*. 2006; 91(11):4237–4245. [PubMed: 16940456]
7. Ben Salem Hachmi L, Ben Salem Hachmi S, Bouzid C, et al. Hypertension in polycystic ovary syndrome [in French]. *Arch Mal Coeur Vaiss*. 2006; 99(7-8):687–690. [PubMed: 17061445]
8. Hoppin AG, Katz ES, Kaplan LM, Lauwers GY. Case records of the Massachusetts General Hospital. Case 31-2006. A 15-year-old girl with severe obesity. *N Engl J Med*. 2006; 355(15):1593–1602. [PubMed: 17035653]
9. Mortensen M, Rosenfield RL, Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. *J Clin Endocrinol Metab*. 2006; 91(10):3786–3790. [PubMed: 16895960]
10. Harris YS, McDonald SB. An African American female with irregular menses and weight gain. *Pediatr Nurs*. 2006; 32(4):354–357. [PubMed: 16927729]
11. De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. *Hum Reprod*. 2006; 21(9):2252–2256. [PubMed: 16785260]
12. Glueck CJ, Aregawi D, Winiarska M, et al. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. *J Pediatr Endocrinol Metab*. 2006; 19(6):831–842. [PubMed: 16886591]
13. Glueck CJ, Morrison JA, Friedman LA, Goldenberg N, Stroop DM, Wang P. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. *Metabolism*. 2006; 55(4):508–514. [PubMed: 16546482]
14. Fulghesu AM, Angioni S, Portoghese E, et al. Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome. *Fertil Steril*. 2006; 86(2):398–404. [PubMed: 16769061]
15. Nicoletti A. Paradigm shift. *J Pediatr Adolesc Gynecol*. 2006; 19(4):317–318. [PubMed: 16873041]
16. Vambergue A, Lautier C, Valat AS, Cortet-Rudelli C, Grigorescu F, Dewailly D. Follow-up study of two sisters with type A syndrome of severe insulin resistance gives a new insight into PCOS pathogenesis in relation to puberty and pregnancy outcome: a case report. *Hum Reprod*. 2006; 21(5):1274–1278. [PubMed: 16410336]
17. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. *J Clin Endocrinol Metab*. 2006; 91(4):1275–1283. [PubMed: 16449341]
18. Mastorakos G, Koliopoulos C, Deligeorgiou E, Diamanti-Kandar-akis E, Creatas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. *Fertil Steril*. 2006; 85(2):420–427. [PubMed: 16595221]
19. Yoo RY, Dewan A, Basu R, Newfield R, Gottschalk M, Chang RJ. Increased luteinizing hormone pulse frequency in obese oligo-menorrhic girls with no evidence of hyperandrogenism. *Fertil Steril*. 2006; 85(4):1049–1056. [PubMed: 16580394]
20. Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. *Arch Pediatr Adolesc Med*. 2006; 160(3):241–246. [PubMed: 16520442]

21. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. *J Clin Endocrinol Metab.* 2006; 91(2):492–497. [PubMed: 16249280]
22. Triantafyllopoulou M, Whittington PF, Melin-Aldana H, Benya EC, Brickman W. Hepatic adenoma in an adolescent with elevated androgen levels. *J Pediatr Gastroenterol Nutr.* 2007; 44(5):640–642. [PubMed: 17460501]
23. Demirel F, Bideci A, Cinaz P, et al. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. *Clin Endocrinol (Oxf).* 2007; 67(1):129–134. [PubMed: 17465999]
24. Sun L, Fu Q. Three-dimensional transrectal ultrasonography in adolescent patients with polycystic ovarian syndrome. *Int J Gynaecol Obstet.* 2007; 98(1):34–38. [PubMed: 17459387]
25. Luque-Ramírez M, Alvarez-Blasco F, Mendieta-Azcona C, Botella-Carretero JI, Escobar-Morreale HF. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2007; 92(6):2141–2148. [PubMed: 17389696]
26. Nazari T, Bayat R, Hamed M. Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial. *Arch Iran Med.* 2007; 10(2):176–181. [PubMed: 17367220]
27. Littlejohn EE, Weiss RE, Deplewski D, Edidin DV, Rosenfield R. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. *J Pediatr Endocrinol Metab.* 2007; 20(1):41–51. [PubMed: 17315528]
28. Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. *Saudi Med J.* 2007; 28(7):1039–1043. [PubMed: 17603706]
29. Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. *Hypertension.* 2007; 49(6):1442–1447. [PubMed: 17389259]
30. Rachmiel M, Kives S, Atenafu E, Hamilton J. Primary amenorrhea as a manifestation of polycystic ovarian syndrome in adolescents: a unique subgroup? *Arch Pediatr Adolesc Med.* 2008; 162(6):521–525. [PubMed: 18524741]
31. Bhattacharya SM. Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. *J Obstet Gynaecol Res.* 2008; 34(1):62–66. [PubMed: 18226131]
32. Ibáñez L, López-Bermejo A, Callejo J, et al. Polycystic ovaries in nonobese adolescents and young women with ovarian androgen excess: relation to prenatal growth. *J Clin Endocrinol Metab.* 2008; 93(1):196–199. [PubMed: 17956949]
33. Valdés P, Cerda A, Barrenechea C, Kehr M, Soto C, Salazar LA. No association between common Gly972Arg variant of the insulin receptor substrate-1 and polycystic ovary syndrome in Southern Chilean women. *Clin Chim Acta.* 2008; 390(1-2):63–66. [PubMed: 18222120]
34. Rossi B, Sukalich S, Droz J, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2008; 93(12):4780–4786. [PubMed: 18812482]
35. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. *Fertil Steril.* 2009; 92(2):626–634. [PubMed: 18706545]
36. Hart R, Doherty DA, Norman RJ, et al. Serum antimüllerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). *Fertil Steril.* 2010; 94(3):1118–1121. [PubMed: 20060112]
37. Huang J, Ni R, Chen X, Huang L, Mo Y, Yang D. Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China. *Reprod Biol Endocrinol.* 2010; 8:142. [PubMed: 21083920]

38. Shah B, Parnell L, Milla S, Kessler M, David R. Endometrial thickness, uterine, and ovarian ultrasonographic features in adolescents with polycystic ovarian syndrome. *J Pediatr Adolesc Gynecol.* 2010; 23(3):146–152. [PubMed: 19733099]
39. Li L, Chen X, Mo Y, Chen Y, Wenig M, Yang D. Elevated serum antimullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. *Wien Klin Wochenschr.* 2010; 122(17–18):519–524. [PubMed: 20809108]
40. Bekx MT, Connor EC, Allen DB. Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovarian syndrome. *J Pediatr Adolesc Gynecol.* 2010; 23(1):7–10. [PubMed: 19648034]
41. Bhattacharya SM, Jha A. Prevalence and risk of metabolic syndrome in adolescent Indian girls with polycystic ovary syndrome using the 2009 ‘joint interim criteria’. *J Obstet Gynaecol Res.* 2011; 37(10):1303–1307. [PubMed: 21535308]
42. Bronstein J, Tawdekar S, Liu Y, Pawelczak M, David R, Shah B. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. *J Pediatr Adolesc Gynecol.* 2011; 24(1):15–20. [PubMed: 21262477]
43. Hart R, Doherty DA, Mori T, et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. *Fertil Steril.* 2011; 95(7):2347–2353, e1. [PubMed: 21450287]
44. Hickey M, Doherty DA, Atkinson H, et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. *Hum Reprod.* 2011; 26(6):1469–1477. [PubMed: 21478180]
45. Morrison JA, Glueck CJ, Daniels S, Wang P, Stroop D. Adolescent oligomenorrhea in a biracial schoolgirl cohort: a simple clinical parameter predicting impaired fasting glucose plus type 2 diabetes mellitus, insulin, glucose, insulin resistance, and centripetal obesity from age 19 to 25 years. *Metabolism.* 2011; 60(9):1285–1293. [PubMed: 21419463]
46. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. *J Pediatr Adolesc Gynecol.* 2011; 24(4):223–227. [PubMed: 21600812]
47. Codner E, Villarroel C, Eyzaguirre FC, et al. Polycystic ovarian morphology in postmenarchal adolescents. *Fertil Steril.* 2011; 95(2):702–706. e1–e2. [PubMed: 20650451]
48. Jones GL, Hall JM, Lashen HL, Balen AH, Ledger WL. Health-related quality of life among adolescents with polycystic ovary syndrome. *J Obstet Gynecol Neonatal Nurs.* 2011; 40(5):577–588.
49. Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. *Fertil Steril.* 2011; 95(3):1059–1066. e1–e7. [PubMed: 21193187]
50. Forrester-Dumont K, Galescu O, Kolesnikov A, et al. Hyperandrogenism does not influence metabolic parameters in adolescent girls with PCOS. *Int J Endocrinol.* 2012; 2012:434830. [PubMed: 22536232]
51. Nair MK, Pappachan P, Balakrishnan S, Leena ML, George B, Russell PS. Menstrual irregularity and polycystic ovarian syndrome among adolescent girls—a 2 year follow-up study. *Indian J Pediatr.* 2012; 79(Suppl 1):S69–S73. [PubMed: 21769526]
52. Rahmanpour H, Jamal L, Mousavinasab SN, Esmailzadeh A, Azarkhish K. Association between polycystic ovarian syndrome, overweight, and metabolic syndrome in adolescents. *J Pediatr Adolesc Gynecol.* 2012; 25(3):208–212. [PubMed: 22578482]
53. Villa P, Rossodivita A, Sagnella F, et al. Ovarian volume and glucoinsulinaemic markers in the diagnosis of PCOS during adolescence. *Clin Endocrinol (Oxf).* 2013; 78(2):285–290. [PubMed: 22724514]
54. Pinola P, Lashen H, Bloigu A, et al. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study *Hum Reprod.* 2012; 27(11):3279–3286.
55. Brown M, Park AS, Shayya RF, Wolfson T, Su HI, Chang RJ. Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age-matched controls. *J Magn Reson Imaging.* 2013; 38(3):689–693. [PubMed: 23292744]

56. Li L, Chen X, He Z, Zhao X, Huang L, Yang D. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents. *J Pediatr Adolesc Gynecol.* 2012; 25(6):390–395. [PubMed: 23089573]
57. Geier LM, Bekx MT, Connor EL. Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome. *J Pediatr Adolesc Gynecol.* 2012; 25(6):367–370. [PubMed: 23089571]
58. Jakubowski KP, Black JJ, El Nokali NE, et al. Parents' readiness to change affects BMI reduction outcomes in adolescents with polycystic ovary syndrome. *J Obes.* 2012; 2012:298067. [PubMed: 22970350]
59. Nandalike K, Agarwal C, Strauss T, et al. Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. *Sleep Med.* 2012; 13(10):1307–1312. [PubMed: 22921588]
60. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Effect of holistic yoga program on anxiety symptoms in adolescent girls with polycystic ovarian syndrome: A randomized control trial. *Int J Yoga.* 2012; 5(2):112–117. [PubMed: 22869994]
61. To WW, Wong MW. A comparison of bone mineral density in normal weight and obese adolescents with polycystic ovary syndrome. *J Pediatr Adolesc Gynecol.* 2012; 25(4):248–253. [PubMed: 22840935]
62. Nidhi R, Padmalatha V, Nagarathna R, Ram A. Effect of a yoga program on glucose metabolism and blood lipid levels in adolescent girls with polycystic ovary syndrome. *Int J Gynaecol Obstet.* 2012; 118(1):37–41. [PubMed: 22507264]
63. Ganie MA, Farooqui KJ, Bhat MA, et al. Pattern of urinary albumin excretion in normotensive young and adolescent Indian women with polycystic ovary syndrome. *Indian J Endocrinol Metab.* 2012; 16(2):277–282. [PubMed: 22470868]
64. Sopher AB, Gerken AT, Blaner WS, Root JM, McMahon DJ, Oberfield SE. Metabolic manifestations of polycystic ovary syndrome in nonobese adolescents: retinol-binding protein 4 and ectopic fat deposition. *Fertil Steril.* 2012; 97(4):1009–1015. [PubMed: 22341881]
65. Deveer R, Engin-Üstün Y, Uysal S, et al. Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary syndrome. *Gynecol Endocrinol.* 2012; 28(8):602–605. [PubMed: 22316276]
66. Eleftheriadou M, Michala L, Stefanidis K, Iliadis I, Lykeridou A, Antsaklis A. Exercise and sedentary habits among adolescents with PCOS. *J Pediatr Adolesc Gynecol.* 2012; 25(3):172–174. [PubMed: 22260889]
67. Bechtold S, Dalla Pozza R, Putzker S, et al. Effect of antiandrogen treatment on bone density and bone geometry in adolescents with polycystic ovary syndrome. *J Pediatr Adolesc Gynecol.* 2012; 25(3):175–180. [PubMed: 22260890]
68. de Sousa G, Schlüter B, Menke T, Trowitzsch E, Andler W, Reinehr T. Longitudinal analyses of polysomnographic variables, serum androgens, and parameters of glucose metabolism in obese adolescents with polycystic ovarian syndrome. *Sleep Breath.* 2012; 16(4):1139–1146. [PubMed: 22102291]
69. Pawelczak M, Kenigsberg L, Milla S, Liu YH, Shah B. Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. *J Pediatr Endocrinol Metab.* 2012; 25(9-10):983–989. [PubMed: 23426830]
70. Roe AH, Prochaska E, Smith M, Sammel M, Dokras A. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. *J Pediatr.* 2013; 162(5):937–941. [PubMed: 23260096]
71. Milsom SR, Nair SM, Ogilvie CM, Stewart JM, Merry SN. Polycystic ovary syndrome and depression in New Zealand adolescents. *J Pediatr Adolesc Gynecol.* 2013; 26(3):142–147. [PubMed: 23452749]
72. Auble B, Elder D, Gross A, Hillman JB. Differences in the management of adolescents with polycystic ovary syndrome across pediatric specialties. *J Pediatr Adolesc Gynecol.* 2013; 26(4):234–238. [PubMed: 23726135]
73. Zachurzok A, Deja G, Gawlik A, Drosdzol-Cop A, Małeczka-Tendera E. Hyperandrogenism in adolescent girls with type 1 diabetes mellitus treated with intensive and continuous subcutaneous insulin therapy. *Endokrynol Pol.* 2013; 64(2):121–128. [PubMed: 23653275]

74. Jeon YE, Lee KE, Jung JA, et al. Kisspeptin, leptin, and retinol-binding protein 4 in women with polycystic ovary syndrome. *Gynecol Obstet Invest.* 2013; 75(4):268–274. [PubMed: 23571154]
75. Christensen SB, Black MH, Smith N, et al. Prevalence of polycystic ovary syndrome in adolescents. *Fertil Steril.* 2013; 100(2):470–477. [PubMed: 23756098]
76. Kale-Gurbuz T, Akhan SE, Bastu E, Telci A, Iyibozkurt AC, Topuz S. Adiponectin, leptin and ghrelin levels in obese adolescent girls with polycystic ovary syndrome. *J Pediatr Adolesc Gynecol.* 2013; 26(1):27–30. [PubMed: 23158749]
77. Bredella MA, McManus S, Misra M. Impact of metformin mono-therapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. *Clin Endocrinol (Oxf).* 2013; 79(2):199–203.
78. Yin Q, Chen X, Li L, Zhou R, Huang J, Yang D. Apolipoprotein B/apolipoprotein A1 ratio is a good predictive marker of metabolic syndrome and pre-metabolic syndrome in Chinese adolescent women with polycystic ovary syndrome. *J Obstet Gynaecol Res.* 2013; 39(1):203–209. [PubMed: 22672648]
79. Flannery CA, Rackow B, Cong X, Duran E, Selen DJ, Burgert TS. Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. *Pediatr Diabetes.* 2013; 14(1):42–49. [PubMed: 22925367]
80. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. *Am J Obstet Gynecol.* 2010; 203(3):e1–e5. [PubMed: 20435290]
81. Hardy TS, Norman RJ. Diagnosis of adolescent polycystic ovary syndrome. *Steroids.* 2013; 78(8):751–754. [PubMed: 23624032]
82. Sultan C, Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls. *Fertil Steril.* 2006; 86(Suppl 1):S6. [PubMed: 16798287]
83. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertil Steril.* 2012; 97(Suppl 1):28.e25–38.e25. [PubMed: 22153789]
84. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. *J Clin Endocrinol Metab.* 2007; 92(2):405–413. [PubMed: 17090633]
85. Biro FM, Emans SJ. Whither PCOS? The challenges of establishing hyperandrogenism in adolescent girls. *J Adolesc Health.* 2008; 43(2):103–105. [PubMed: 18639782]
86. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. *Hum Reprod Update.* 2010; 16(1):51–64. [PubMed: 19567450]
87. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2008; 93(4):1105–1120. [PubMed: 18252793]
88. Merino PM, Codner E, Cassorla F. A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence. *Arq Bras Endocrinol Metabol.* 2011; 55(8):590–598. [PubMed: 22218441]
89. Legro RS, Schlaff WD, Diamond MP, et al. Reproductive Medicine Network. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. *J Clin Endocrinol Metab.* 2010; 95(12):5305–5313. [PubMed: 20826578]
90. Janse F, Eijkemans MJ, Goverde AJ, et al. Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. *Eur J Endocrinol.* 2011; 165(6):925–933. [PubMed: 21969522]
91. Haring R, Hannemann A, John U, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. *J Clin Endocrinol Metab.* 2012; 97(2):408–415. [PubMed: 22162468]
92. Kushnir MM, Blamires T, Rockwood AL, et al. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. *Clin Chem.* 2010; 56(7):1138–1147. [PubMed: 20489135]
93. Fanelli F, Gambineri A, Belluomo I, et al. Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late

- adolescent and young women. *J Clin Endocrinol Metab.* 2013; 98(7):3058–3067. [PubMed: 23780369]
94. Apter D, Vihko R. Serum pregnenolone, progesterone, 17-hydrox-yprogesterone, testosterone and 5 alpha-dihydrotestosterone during female puberty. *J Clin Endocrinol Metab.* 1977; 45(5):1039–1048. [PubMed: 925129]
 95. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppelaar C, Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. *Hum Reprod.* 2004; 19(2):383–392. [PubMed: 14747186]
 96. Rosenfield RL. Clinical review: Adolescent anovulation: maturational mechanisms and implications. *J Clin Endocrinol Metab.* 2013; 98(9):3572–3583. [PubMed: 23913942]
 97. Jeffrey Chang R, Coffler MS. Polycystic ovary syndrome: early detection in the adolescent. *Clin Obstet Gynecol.* 2007; 50(1):178–187. [PubMed: 17304035]
 98. Hassan A, Gordon CM. Polycystic ovary syndrome update in adolescence. *Curr Opin Pediatr.* 2007; 19(4):389–397. [PubMed: 17630601]
 99. Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. *Human Reprod.* 2001; 26(11):3123–3129.
 100. Johnstone EB, Rosen MP, Neril R, et al. The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. *J Clin Endocrinol Metab.* 2010; 95(11):4965–4972. [PubMed: 20719841]
 101. Villarroel C, Merino PM, López P, et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. *Hum Reprod.* 2011; 26(10):2861–2868. [PubMed: 21784736]
 102. Williams RM, Ong KK, Dunger DB. Polycystic ovarian syndrome during puberty and adolescence. *Mol Cell Endocrinol.* 2013; 373(1–2):61–67. [PubMed: 23384539]
 103. Chen Y, Yang D, Li L, Chen X. The role of ovarian volume as a diagnostic criterion for Chinese adolescents with polycystic ovary syndrome. *J Pediatr Adolesc Gynecol.* 2008; 21(6):347–350. [PubMed: 19064229]
 104. Yoo RY, Sirlin CB, Gottschalk M, Chang RJ. Ovarian imaging by magnetic resonance in obese adolescent girls with polycystic ovary syndrome: a pilot study. *Fertil Steril.* 2005; 84(4):985–995. [PubMed: 16213854]
 105. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? *Hum Reprod.* 2012; 27(8):2494–2502. [PubMed: 22693172]
 106. Huang G, Coviello A. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. *Curr Opin Endocrinol Diabetes Obes.* 2012; 19(6):512–519. [PubMed: 23108199]
 107. Hoeger KM, Oberfield SE. Do women with PCOS have a unique predisposition to obesity? *Fertil Steril.* 2012; 97(1):13–17. [PubMed: 22192136]
 108. Nicandri KF, Hoeger K. Diagnosis and treatment of polycystic ovarian syndrome in adolescents. *Curr Opin Endocrinol Diabetes Obes.* 2012; 19(6):497–504. [PubMed: 23076041]
 109. Glueck CJ, Morrison JA, Daniels S, Wang P, Stroop D. Sex hormone-binding globulin, oligomenorrhea, polycystic ovary syndrome, and childhood insulin at age 14 years predict metabolic syndrome and class III obesity at age 24 years. *J Pediatr.* 2011; 159(2):308–313, e2. [PubMed: 21362574]
 110. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. *J Clin Endocrinol Metab.* 2007; 92(12):4546–4556. [PubMed: 18056778]
 111. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2002; 87(3):1017–1023. [PubMed: 11889155]

Table 1
Review of diagnosis of PCOS in adolescents (2006–2013)^{7–79}

• Number of studies: 69; case reports: 4
• Criteria used ^a
– NIH 22
– Rotterdam 42
– AES/other 8
– Not specified 7
• Nationality
– USA 30, Canada 1, Chile 2, France 1, Italy 4, Spain 2, Finland 1, Germany 2, England 1, Poland 1, Tunisia 1, India 7, Greece 2, Turkey 3, Iran 2, Saudi Arabia 1, China 5, Taiwan 1, Hong Kong 1, Korea 1, Australia 3, New Zealand 1
• Study size: 1-1,563 subjects
• Mean age of subjects
– 15.1–29.1 y: 64 studies
– < 25 y: 62 studies
• Time since menarche: 0.5-5 y (22/73 data available)

Abbreviations: AES, Androgen Excess Society; NIH, National Institute of Health, PCOS, polycystic ovary syndrome.

^a Five of the above mentioned articles used multiple criteria.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript